Photo of Jean-Frederic Colombel

Jean-Frederic Colombel

  • SENIOR FACULTY Medicine, Gastroenterology
Print ProfilePrint Profile

Specialty

Biography

    Over the past 20 years I have set up in Lille (France) together with my colleagues a successful comprehensive research and health care network fully dedicated to Inflammatory Bowel Diseases (Crohn’s disease [CD] and ulcerative colitis [UC]). Our research center was composed of 3 complementary groups: (1) a medical and surgical department which has performed many multicenter studies at the national (GETAID group) and international level; (2) an epidemiological group based upon the IBD North-Western Registry (EPIMAD); (3) a physiopathological group devoted to the study of immunological mechanisms and the development of new therapeutic targets in regulation of digestive inflammation. Thanks to the development of multiple local, national and international collaborations we have been able to make some important contributions to the pathophysiology of IBD. The most remarkable are the initiation in 1994 of collection and sampling of IBD families that eventually led to the identificationof NOD2 as a susceptibility gene for CD, the development in the 90’s of the ASCA test (anti-S. cerevisiae (mannan) antibodies) which is still the most sensitive and specific serologic marker for CD and elucidation of the potential role of Candida albicans in CD and the identification of a new pathovar of Escherichia coli (AIEC for adhesive invasive E.coli) associated with ileal CD. At the national level, I have been one of the leaders of the GETAID group, initiating and participating to many clinical trials that have helped to improve therapeutic strategies in IBD especially regarding the use of immunomodulators and biologics. Apart from international recognition, one of the biggest achievement of the GETAID has been the

    The main concretisation of this work has been the publication as primary author or co-author of more than 500 peer-reviewed papers and 30 chapters of books most of them in the domain of IBD. I have been invited to give talks in many countries either during IBD meetings or national and international meetings including UEGW and DDW. I have been and am still in the editorial board of several gastroenterology journals including Clinical Gastroenterology and Hepatology, Nature reviews in Gastroenterology and Hepatology, Inflammatory Bowel Disease and Journal of Crohn’s and Colitis. I have been associate editor of Gut from 2005 to 2009 and I am currently associate editor of Alimentary Pharmacology and Therapeutics being in charge of IBD papers. This leadership in IBD has been recognized by my colleagues who elected me as the president of ECCO (2008-2010) and chair of the International Organisation of Inflammatory Bowel Disease (IOIBD) (2010-current). I have been appointed at the director of the Helmsley IBD center at Mount Sinai since January 1, 2013.

Publications

.;.

Beaudoin M, Goyette P, Boucher G, Lo KS, Rivas MA, Stevens C, Alikashani A, Ladouceur M, Ellinghaus D, Törkvist L, Goel G, Lagacé C, Annese V, Bitton A, Begun J, Brant SR, Bresso F, Cho JH, Duerr RH, Halfvarson J, McGovern DP, Radford-Smith G, Schreiber S, Schumm PL, Sharma Y, Silverberg MS, Weersma RK, D'Amato M, Vermeire S, Franke A, Lettre G, Xavier RJ, Daly MJ, Rioux JD. Deep resequencing of GWAS loci identifies rare variants in CARD9, IL23R and RNF186 that are associated with ulcerative colitis. PLoS genetics 2013; 9(9).

Beaugerie L, Carrat F, Colombel JF, Bouvier AM, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron JL, Simon T, de Gramont A, Peyrin-Biroulet L. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014 Sep; 63(9).

Bernheim O, Colombel JF, Ullman TA, Laharie D, Beaugerie L, Itzkowitz SH. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013 Nov; 62(11).

Billioud V, Ford AC, Tedesco ED, Colombel JF, Roblin X, Peyrin-Biroulet L. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis. Journal of Crohn's & colitis 2013 Dec; 7(11).

Allen PB, Kamm MA, Peyrin-Biroulet L, Studd C, McDowell C, Allen BC, Connell WR, De Cruz PP, Bell SJ, Elliot RP, Brown S, Desmond PV, Lemann M, Colombel JF. Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. Alimentary pharmacology & therapeutics 2013 Feb; 37(4).

.;.

De Vroey B, Gower-Rousseau C, Colombel JF. Exploring life before IBD. Gut 2013 May; 62(5).

Danese S, Colombel JF, Peyrin-Biroulet L, Rutgeerts P, Reinisch W. Review article: the role of anti-TNF in the management of ulcerative colitis -- past, present and future. Alimentary pharmacology & therapeutics 2013 May; 37(9).

Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013 Oct; 145(4).

Colombel JF, Sendid B, Jouault T, Poulain D. Secukinumab failure in Crohn's disease: the yeast connection?. Gut 2013 May; 62(5).

Legraverend JM, Canarelli JP, Boudailliez B, Ricard Y, Collet LM, Bove N. [Cavernous hemangioma of the bladder in children. Apropos of a case]. Annales d'urologie 1986; 20(4).

Bouguen G, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2013 Sep;.

Boualit M, Salleron J, Turck D, Fumery M, Savoye G, Dupas JL, Lerebours E, Duhamel A, Merle V, Cortot A, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C. Long-term outcome after first intestinal resection in pediatric-onset Crohn's disease: a population-based study. Inflammatory bowel diseases 2013 Jan; 19(1).

.;.

Gerard R, Sendid B, Colombel JF, Poulain D, Jouault T. An immunological link between Candida albicans colonization and Crohn's disease. Critical reviews in microbiology 2013 Jul;.

Gensollen T, Bourges C, Rihet P, Rostan A, Millet V, Noguchi T, Bourdon V, Sobol H, Dubuquoy L, Bertin B, Fumery M, Desreumaux P, Colombel JF, Chamaillard M, Hebuterne X, Hofman P, Naquet P, Galland F. Functional polymorphisms in the regulatory regions of the VNN1 gene are associated with susceptibility to inflammatory bowel diseases. Inflammatory bowel diseases 2013 Oct; 19(11).

Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology 2013 Nov; 145(5).

Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, Van Assche G, Axler J, Kim HJ, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A. Vedolizumab as induction and maintenance therapy for ulcerative colitis. The New England journal of medicine 2013 Aug; 369(8).

Dussault C, Gower-Rousseau C, Salleron J, Vernier-Massouille G, Branche J, Colombel JF, Maunoury V. Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2013 Jul; 45(7).

Bell WJ. On being two hundred 1787-1987. Transactions & studies of the College of Physicians of Philadelphia 1987 Mar; 9(1).

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Colombel during 2013 and/or 2014. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Consulting:

  • Abbott Laboratories; Bristol-Myers Squibb; Celgene Corporation; Genentech, Inc.; Giuliani S.p.A.; Hospira, Inc.; Merck & Co., Inc.; Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company Limited ); Nestlé; Pfizer Inc.; Receptos Inc.; Schering-Plough (Merck & Co., Inc.); Teva Pharmaceutical Industries Ltd.; UCB S.A.; sanofi-aventis

Industry-Sponsored Lectures: MSSM faculty occasionally give lectures at events sponsored by industry, but only if the events are free of any marketing purpose.

  • Abbott Laboratories; Ferring Pharmaceuticals; Merck & Co., Inc.; Schering-Plough (Merck & Co., Inc.)

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Intestinal Biotech Development

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central